Lifestyle Medicine in Tuberculosis Care in Viet Nam: Nutritional Support, Treatment Continuity, and Transmission Prevention

Lifestyle Medicine in Tuberculosis Care in Viet Nam: Nutritional Support, Treatment Continuity, and Transmission Prevention

Primary category: Evidence & Clinical Practice

Secondary category: Lifestyle Medicine in Viet Nam

Article type: VLMA Perspective

Last reviewed: October 30, 2026

A tuberculosis diagnosis can disrupt much more than a person's health. Someone who previously worked every day may suddenly need repeated medical appointments, several months of treatment, and time away from work. Loss of appetite and weight may make ordinary activities difficult. At home, family members may worry about infection, while the person receiving treatment may be uncertain about when it is safe to return to work or spend time with others.

Even when effective medicines are available, completing treatment can be challenging. Adverse drug effects, transportation costs, reduced income, inadequate food, and concerns about disclosure of the diagnosis may all affect treatment continuity. These difficulties can also influence recovery and the well-being of the entire household.

Lifestyle Medicine has a supporting role in this situation, but its boundaries must be clear. Tuberculosis is caused by Mycobacterium tuberculosis and requires appropriate medical treatment. Healthy eating, physical activity, adequate sleep, and stress management do not eliminate the bacteria or replace effective anti-tuberculosis medication.

Nutrition, tobacco cessation, psychological support, and attention to living conditions can nevertheless contribute to comprehensive tuberculosis care. In some circumstances, food assistance and other practical support may also help people affected by the disease.

For healthcare professionals in Viet Nam, the opportunity is to connect these interventions with established tuberculosis services while maintaining treatment safety, preventing transmission, and addressing the circumstances that make recovery difficult.

Tuberculosis Is an Infectious Disease, Not a Failure of Healthy Living

Tuberculosis most commonly affects the lungs, although it can also involve the lymph nodes, bones, central nervous system, kidneys, and other organs.

Pulmonary tuberculosis may cause a prolonged cough, fever, night sweats, weight loss, fatigue, or other respiratory symptoms. Some people experience relatively mild symptoms despite clinically important disease, which can delay recognition.

Tuberculosis spreads primarily through inhalation of infectious airborne particles released by people with infectious pulmonary or laryngeal tuberculosis.

Not everyone exposed to the bacteria becomes infected, and not everyone who becomes infected develops active tuberculosis disease.

Tuberculosis infection without evidence of active disease is different from active tuberculosis. People who have tuberculosis infection but do not have active disease are not infectious, although some may develop tuberculosis disease later.

The risk of progression depends on factors including immune function, nutritional status, age, and associated medical conditions. Diagnostic assessment, treatment, and prevention therefore differ according to whether someone has tuberculosis infection or active disease.

Tuberculosis should not be interpreted as evidence that a person has neglected their health.

Transmission depends on exposure to infectious individuals, shared indoor air, ventilation, duration of contact, and other environmental conditions. Undernutrition, diabetes, human immunodeficiency virus infection, and other factors can increase susceptibility or worsen outcomes, but none fully explains why a particular person develops tuberculosis.

Someone may maintain healthy daily habits and still become infected.

Effective tuberculosis care begins with recognizing the disease as a medical and public health problem rather than attributing it to individual lifestyle choices.

Tuberculosis Remains a Major Health Concern in Viet Nam

Tuberculosis continues to impose a substantial health burden in Viet Nam.

The World Health Organization's Global Tuberculosis Report 2025, published on November 12, 2025, identifies Viet Nam among the countries with the highest tuberculosis burden worldwide. [1]

At the national tuberculosis program review on May 7, 2026, the World Health Organization Representative in Viet Nam reported that approximately 119,000 tuberculosis cases had been notified nationally during 2025, the highest number reported to that point. [2]

This figure represents notified cases, not the total estimated number of people who developed tuberculosis.

The World Health Organization also estimated that approximately 180,000 people develop tuberculosis in Viet Nam annually, indicating that a substantial detection gap remains.

An increase in notifications may reflect improvements in screening, diagnosis, reporting, and access to care rather than an equivalent increase in the underlying incidence of disease.

The same event marked the launch of Viet Nam's National Tuberculosis Strategic Plan for 2026–2030.

The strategy emphasizes earlier detection through active case finding, stronger integration with primary healthcare, expanded public–private collaboration, improved preventive treatment, and more sustainable financing. [2]

These priorities provide an important context for understanding the supportive role of Lifestyle Medicine.

Identifying tuberculosis is essential, but diagnosis alone does not guarantee that someone can complete treatment. A person who loses access to medication, develops significant adverse effects, or cannot afford adequate food may continue to face substantial difficulties.

Likewise, completing anti-tuberculosis treatment does not necessarily mean that every nutritional, respiratory, or functional problem has resolved.

Improving tuberculosis outcomes therefore requires effective diagnosis and treatment, appropriate prevention, and attention to recovery.

Effective Anti-Tuberculosis Treatment Remains the Foundation

Tuberculosis is treatable and often curable when an effective regimen is selected and completed appropriately.

Treatment depends on the type and location of tuberculosis, drug susceptibility, disease severity, previous treatment history, and other clinical factors.

Drug-susceptible tuberculosis and drug-resistant tuberculosis cannot be managed as though they were the same condition.

Diagnostic evaluation may involve molecular tests, microbiological examination, culture, and drug-susceptibility testing according to clinical indications and available services.

Identifying resistance is important because an ineffective regimen may fail to control infection, prolong infectiousness, and expose patients to avoidable treatment-related harm.

On September 25, 2026, the World Health Organization published the second edition of WHO Consolidated Guidelines on Tuberculosis: Module 4 — Treatment and Care. [3]

The updated document brings together recommendations for drug-susceptible and drug-resistant tuberculosis, patient care, and treatment support. It also incorporates newer treatment options for selected patients with drug-resistant disease, including shorter regimens in specific clinical circumstances.

The second edition includes updated recommendations for selected forms of drug-resistant tuberculosis, including some patients with pre-extensively drug-resistant disease, as well as recommendations concerning children, adolescents, and supportive or palliative care when appropriate.

These developments demonstrate continued progress in tuberculosis treatment. However, they should not be interpreted as establishing one treatment duration or regimen for every patient.

Some people may qualify for shorter regimens, while others require longer or more complex treatment. Decisions depend on disease characteristics, drug susceptibility, eligibility criteria, clinical safety, and applicable professional guidance.

International recommendations also do not automatically establish that particular medicines or regimens are approved, available, or routinely implemented throughout Viet Nam.

The Ministry of Health's Decision No. 162/QĐ-BYT, issued on January 19, 2024, provides national professional guidance on tuberculosis diagnosis, treatment, and prevention. The decision replaced Decision No. 1314/QĐ-BYT dated March 24, 2020. [4]

For Lifestyle Medicine, the appropriate boundary is clear: supportive interventions can improve aspects of health and recovery, but effective antimicrobial treatment and clinical monitoring remain essential.

Treatment Continuity Depends on More Than Personal Motivation

Tuberculosis treatment commonly continues for several months. During this period, symptoms may improve long before the prescribed regimen has been completed.

Cough, fever, fatigue, and loss of appetite may diminish. Someone who feels substantially better may begin to question why treatment needs to continue.

However, symptom improvement does not establish microbiological cure or justify independently stopping medication.

Treatment interruption, inappropriate dose changes, or use of an ineffective regimen may contribute to treatment failure, recurrence, or other serious consequences.

Drug resistance can arise through several mechanisms, including transmission of resistant strains and the selection of resistance during ineffective treatment. It should not automatically be attributed to individual nonadherence.

The World Health Organization's current guidance emphasizes person-centered treatment support rather than relying exclusively on directly observed treatment. [3]

The purpose is to help people take prescribed medicines successfully through arrangements that reflect their needs, circumstances, and preferences.

Depending on the setting, support may involve counseling, medication reminders, agreed contact with healthcare workers, community-based assistance, digital monitoring, or video-supported treatment.

Some patients may need assistance managing adverse effects. Others may benefit from transportation support, food assistance, or help coordinating appointments with employment and family responsibilities.

These approaches should be selected according to individual needs rather than applied as an identical package for everyone.

Someone who misses an appointment because transportation is unaffordable faces a different problem from a person who misunderstands the medication schedule. Both situations deserve attention, but they may require different solutions.

Treatment support should help identify barriers early, maintain communication, and preserve access to effective medication without placing unnecessary blame on the patient.

Undernutrition Is a Clinical Problem With Wider Social Consequences

Undernutrition and tuberculosis are closely connected.

Tuberculosis can reduce appetite, increase metabolic demands, and contribute to substantial weight loss. At the same time, inadequate nutrition can impair immune function and increase vulnerability to progression from tuberculosis infection to active disease.

The World Health Organization's 2025 tuberculosis and comorbidities guideline cites research estimating that approximately 48% of people with tuberculosis globally experience undernutrition. [5]

This estimate is derived from the studies reviewed, not a measured prevalence for every tuberculosis population or for Viet Nam specifically.

The relationship between undernutrition and tuberculosis is influenced by disease severity, food availability, living conditions, and associated health problems.

Someone may lose weight because of infection-related inflammation, poor appetite, nausea, or gastrointestinal symptoms. Another person may have inadequate food because illness has reduced their ability to work and support the household.

These problems can occur together.

The clinical response should begin with nutritional assessment rather than assuming that everyone with tuberculosis needs the same dietary intervention.

Relevant information includes recent weight changes, current intake, appetite, physical function, nutritional deficiencies, and associated conditions.

For children and adolescents, growth and development must also be considered. Pregnancy, older age, diabetes, human immunodeficiency virus infection, and other medical conditions may alter nutritional needs.

Weight gain during treatment can be a useful sign of nutritional recovery, but it does not independently establish tuberculosis cure.

Persistent weight loss may require reassessment for inadequate nutrition, adverse drug effects, ongoing disease, or another medical condition.

Nutritional care should therefore be monitored alongside the person's wider clinical progress.

The 2025 WHO Nutrition Recommendations Go Beyond Dietary Counseling

On October 7, 2025, the World Health Organization published the second edition of WHO Consolidated Guidelines on Tuberculosis: Module 6 — Tuberculosis and Comorbidities. [5]

The guideline includes updated recommendations on undernutrition in people with tuberculosis and nutritional vulnerability among household contacts.

Importantly, it goes beyond general advice to maintain a balanced diet.

WHO recommends offering nutritional assessment and appropriate counseling to all people with tuberculosis at diagnosis and throughout treatment.

Household contacts should also be offered nutritional assessment and counseling as part of contact investigation, with appropriate management when undernutrition is identified.

The guideline further recommends nutritional interventions for people with tuberculosis who have mild, moderate, or severe undernutrition as part of comprehensive care.

Depending on individual circumstances and available services, these interventions may involve food provision, specially formulated nutritional products, or financial assistance that improves access to food.

The recommendation is strong, although the supporting evidence is of low-to-moderate certainty.

The distinction between the strength of a recommendation and the certainty of the evidence is important. A strong recommendation reflects a judgment about expected benefits, risks, feasibility, and other considerations; it does not mean every supporting study provides high-certainty evidence.

The guidance reflects the importance of addressing undernutrition, but it does not establish that one supplement, nutritional formula, or food basket will provide the same benefit for every person.

It also distinguishes nutritional assessment from actual nutritional assistance.

Counseling can help someone understand their needs and make appropriate dietary choices. However, information alone cannot resolve inadequate food intake when a household lacks sufficient resources.

For implementation in Viet Nam, healthcare organizations need to consider available resources, professional capacity, social support arrangements, and the circumstances of people receiving care.

The WHO recommendations provide an international framework for improving services. They should not be interpreted as evidence that every recommended nutritional support intervention has already been introduced across Vietnamese healthcare facilities.

Nutritional Support Should Match the Person's Needs

A useful nutritional assessment should lead to a practical plan.

For someone with significant weight loss and inadequate food intake, the priority may be improving energy and protein consumption.

Another person may experience nausea, gastrointestinal discomfort, or poor tolerance of meals during treatment. Clinical assessment and management of these symptoms may be necessary before ordinary dietary advice can be effective.

Someone with diabetes may require additional support to manage glucose regulation during tuberculosis treatment.

A person with severe undernutrition may need specialized nutritional rehabilitation and monitoring for complications associated with refeeding.

In Viet Nam, familiar foods such as rice, fish, eggs, tofu, meat, legumes, vegetables, and fruit can contribute to a nutritionally adequate eating pattern. The practical questions are whether the person can obtain sufficient food, whether the diet provides adequate energy and essential nutrients, and whether associated medical conditions require specific adjustments.

There is no established evidence that a particular traditional food, herbal preparation, or so-called immune-boosting diet cures tuberculosis.

Patients should not be encouraged to purchase expensive supplements solely because they are marketed as strengthening immunity or accelerating recovery.

At the same time, specialized nutritional products may be appropriate when ordinary food intake is insufficient or particular clinical needs justify their use.

Vitamin and mineral supplementation also requires appropriate consideration.

Pyridoxine, for example, may be prescribed with isoniazid in selected patients to reduce the risk of peripheral neuropathy. This is a medication-related preventive measure, not a reason for everyone with tuberculosis to independently take high-dose vitamins.

The WHO 2025 guideline also notes that vitamin D supplementation as a tuberculosis-specific intervention remains an area of research. It conditionally supports its use in the context of rigorous research rather than establishing routine vitamin D supplementation as a treatment for tuberculosis. [5]

Supplementation for a documented deficiency or another established clinical indication is a separate matter.

Nutritional support should be based on assessed needs, delivered under appropriate professional responsibility, and reviewed as treatment progresses.

Food Assistance May Benefit the Entire Household

An important development in recent tuberculosis nutrition research concerns household food support.

In 2023, Bhargava and colleagues published the RATIONS trial in The Lancet. The study was conducted in Jharkhand, India, where tuberculosis and undernutrition represented substantial overlapping public health challenges. [6]

The cluster-randomized trial examined whether additional nutritional support for household contacts of people with microbiologically confirmed pulmonary tuberculosis could reduce the development of tuberculosis disease.

The intervention was associated with an approximately 39% relative reduction in the incidence of all forms of tuberculosis among household contacts during follow-up.

This finding was important because it demonstrated the potential for nutritional support to benefit people beyond the individual already receiving tuberculosis treatment.

However, the reported reduction represents a relative effect observed in the trial population. It does not mean that providing food eliminates 39% of tuberculosis cases in every household or produces an identical effect in all countries.

The study took place in a setting with substantial undernutrition and food insecurity. Its results may differ in populations with different nutritional, socioeconomic, and epidemiological circumstances.

The findings also do not establish that food assistance can replace tuberculosis contact investigation, preventive treatment, or airborne infection-control measures.

The WHO 2025 guideline incorporated this evidence and recommends offering food baskets combined with multiple micronutrient supplements to households affected by tuberculosis in settings of food insecurity. [5]

This is a strong recommendation supported by moderate-certainty evidence.

The recommendation concerns the household as a whole, including the person receiving tuberculosis treatment, rather than only those contacts who have already been identified as undernourished.

For Viet Nam, the finding raises a practical question: when food insecurity affects people receiving tuberculosis treatment and their households, how can healthcare services recognize the problem and connect them with suitable assistance?

The answer does not necessarily require every tuberculosis clinic to operate its own food assistance program.

Healthcare organizations may collaborate with appropriate public health services, social support programs, and community partners where such arrangements are available and lawful.

The purpose is to address nutritional vulnerability without confusing social assistance with antimicrobial treatment or established tuberculosis prevention services.

Medication Safety Is Part of Maintaining Treatment Continuity

Anti-tuberculosis medicines can cause adverse effects, and the risks differ between regimens.

Some patients experience nausea, reduced appetite, or gastrointestinal discomfort. Others may develop liver injury, peripheral neuropathy, visual disturbances, allergic reactions, or other complications requiring clinical assessment.

Certain drug-resistant tuberculosis regimens have additional safety considerations, including cardiac, neurological, or hematological effects.

These risks should neither be minimized nor used to discourage necessary treatment.

Before treatment begins, patients should receive understandable information about the prescribed regimen, expected monitoring, and symptoms requiring professional review.

The Ministry of Health's tuberculosis guidance issued under Decision No. 162/QĐ-BYT addresses adverse drug reactions and their management. [4]

Jaundice, severe or persistent vomiting, significant visual changes, severe skin reactions, unusual neurological symptoms, or other substantial deterioration may require urgent clinical assessment.

The response depends on the medicine involved, the suspected adverse effect, and its severity.

Some complications can be managed while effective treatment continues. Others may require specialist-directed changes to the regimen.

A general educational article should not instruct patients to stop a specific tuberculosis medicine, change its dose, or substitute another product independently.

Traditional medicines, herbal preparations, and supplements also deserve attention because their composition, potential liver toxicity, and interactions with anti-tuberculosis medicines may be uncertain.

A product promoted as protecting the liver should not be assumed to prevent drug-induced liver injury.

Medication safety requires timely identification of adverse effects, appropriate clinical monitoring, and preservation of an effective treatment regimen whenever possible.

Smoking, Alcohol, and Associated Diseases Can Complicate Recovery

Tobacco use and harmful alcohol consumption are relevant concerns in tuberculosis care.

Smoking is associated with increased tuberculosis risk and adverse respiratory outcomes. For someone with pulmonary tuberculosis, smoking may worsen respiratory health and contribute to long-term lung problems.

Smoking cessation is therefore an important component of comprehensive care. Effective support may involve counseling and appropriate evidence-based treatment rather than brief advice alone.

Alcohol consumption requires attention for different reasons.

Harmful alcohol use may contribute to liver injury, interfere with daily functioning, and complicate treatment continuity. Some anti-tuberculosis medicines are also hepatotoxic, making alcohol-related risks particularly relevant.

However, alcohol dependence should not be approached through blame or moral judgment.

A person with significant dependence may require structured treatment and, in some circumstances, medical supervision during withdrawal.

Diabetes is another important comorbidity because it can increase susceptibility to tuberculosis disease and complicate clinical outcomes. Appropriate assessment and management of glucose regulation may therefore be necessary.

Human immunodeficiency virus infection also requires coordinated care, including consideration of antiretroviral treatment, possible drug interactions, and other relevant health needs.

These concerns require clinical management rather than generic lifestyle recommendations.

The role of Lifestyle Medicine is to support healthier behaviors and help address associated risks without distracting from effective tuberculosis treatment.

Physical Activity Can Support Recovery, but Timing Matters

Tuberculosis can reduce physical capacity during treatment and after microbiological cure.

Weight loss, inadequate nutritional intake, prolonged illness, and reduced activity may contribute to muscle weakness and fatigue. Some people also experience persistent breathlessness or reduced exercise tolerance after completing treatment.

Appropriate movement and physical rehabilitation may help selected patients recover strength, endurance, and daily functioning.

However, no exercise program eliminates tuberculosis bacteria or replaces antimicrobial therapy.

The decision to resume or increase physical activity should reflect clinical stability, nutritional status, respiratory symptoms, associated conditions, and the person's physical capacity.

Someone who is severely unwell, markedly breathless, or experiencing substantial weight loss may need medical reassessment and nutritional support before undertaking demanding exercise.

For a person whose condition has improved, gradual activity may be appropriate, with progression according to tolerance and professional guidance.

Transmission risk must also be considered.

Someone who may still have infectious pulmonary tuberculosis should not automatically attend indoor group exercise sessions or activities involving prolonged close contact.

The timing of return to shared activities should follow assessment by the responsible tuberculosis service and applicable infection-control requirements.

After treatment, some people experience persistent respiratory abnormalities, often described as post-tuberculosis lung disease. These may include chronic respiratory symptoms, impaired lung function, or reduced exercise capacity.

Selected patients may benefit from respiratory assessment and pulmonary rehabilitation when clinically indicated.

However, rehabilitation should not be assumed necessary for everyone who completes tuberculosis treatment.

The objective is to support recovery while recognizing when persistent symptoms require assessment for complications, recurrent disease, or another medical condition.

Tuberculosis Prevention Must Address Airborne Transmission

Effective transmission prevention depends on understanding how tuberculosis spreads.

People with infectious pulmonary or laryngeal tuberculosis can release bacteria-containing particles into the air when breathing, coughing, speaking, singing, or performing other respiratory activities.

People sharing the same indoor air may inhale these particles, particularly when exposure is prolonged and ventilation is inadequate.

Tuberculosis is not ordinarily transmitted through sharing food, dishes, utensils, or routine physical contact.

This distinction matters because inaccurate beliefs can lead to unnecessary household restrictions while more important airborne precautions are overlooked.

WHO guidance on tuberculosis infection prevention and control emphasizes administrative measures, environmental controls, and respiratory protection. [7,8]

Administrative measures include early recognition of suspected infectious tuberculosis, appropriate separation when indicated, and prompt initiation of effective treatment.

Environmental measures aim to reduce concentrations of infectious airborne particles through suitable ventilation and other controls appropriate to the setting.

Respiratory protection is important in healthcare facilities and other environments where exposure risk is significant.

Medical masks worn by people with suspected or confirmed infectious tuberculosis may contribute to source control. Appropriately selected and fitted particulate respirators, such as N95 or equivalent respirators, provide respiratory protection for healthcare workers in relevant higher-risk circumstances.

These measures serve different purposes and should not be treated as interchangeable.

Hand hygiene and cough etiquette remain useful general infection-prevention practices. However, tuberculosis prevention depends primarily on controlling the airborne transmission pathway.

Cleaning surfaces or disinfecting utensils cannot compensate for inadequate ventilation, delayed recognition of infectious tuberculosis, or insufficient respiratory protection.

For healthcare organizations, the priority is to ensure that prevention measures reflect actual risk and are implemented through appropriate professional procedures.

Household Precautions Should Be Practical and Proportionate

Someone receiving tuberculosis treatment may live in a crowded household, share sleeping space, or have limited control over ventilation.

Advice to use a separate room may be difficult or impossible to follow.

Healthcare professionals should recognize these circumstances and help households identify feasible measures based on the person's infectiousness and living conditions.

Where practical, improving ventilation, reducing prolonged close indoor exposure while the person remains infectious, and following appropriate masking recommendations can help reduce risk.

Environmental measures should also account for outdoor air quality, weather conditions, building design, and household safety.

Additional attention may be needed when young children, older people, or individuals with conditions increasing tuberculosis risk share the household.

The duration of precautions requires individualized assessment.

A person should not automatically be declared noninfectious simply because treatment has started, a fixed number of days has passed, or coughing has decreased.

Infectiousness depends on clinical, microbiological, and treatment-related factors, including the extent and location of disease, bacterial burden, drug susceptibility, effectiveness of treatment, and clinical response.

Drug-resistant tuberculosis may require additional precautions.

Decisions about isolation, returning to work or school, and participating in shared activities should follow the assessment of the responsible clinical and public health services rather than an arbitrary timeline.

Precautions should protect others without becoming unnecessarily prolonged, stigmatizing, or punitive.

The objective is to reduce transmission while preserving dignity, communication, and access to necessary care.

Household Contact Investigation and Preventive Treatment Are Essential

When someone is diagnosed with infectious pulmonary tuberculosis, identifying and assessing household contacts becomes an important part of care.

Some contacts may already have active tuberculosis without recognizing their symptoms. Others may have tuberculosis infection without evidence of active disease.

Appropriate contact investigation can help identify these situations and determine whether further testing, clinical assessment, or preventive treatment is required.

Children and people with impaired immune function deserve particular attention because of their risk of progression to active tuberculosis.

The WHO tuberculosis preventive treatment guideline, updated in September 2024, provides recommendations for identifying eligible individuals, excluding active disease, selecting appropriate preventive regimens, and monitoring treatment safety. [9]

It also addresses prevention among contacts exposed to multidrug-resistant or rifampicin-resistant tuberculosis.

Tuberculosis preventive treatment differs from treatment of active disease and must be selected through appropriate clinical and public health arrangements.

It cannot be replaced by nutrition, exercise, or general health education.

Vaccination also remains relevant.

Bacille Calmette–Guérin vaccination is included in appropriate national immunization programs, particularly to protect young children against severe forms of tuberculosis.

However, vaccination does not eliminate every risk of tuberculosis infection or disease and does not replace contact investigation or preventive treatment when indicated.

The 2025 WHO nutrition guidance adds another consideration by recommending nutritional assessment of household contacts and food assistance in relevant settings of food insecurity. [5]

A household may therefore require several forms of support: assessment for tuberculosis, preventive treatment for eligible contacts, airborne precautions, and nutritional assistance.

These activities serve different purposes, but coordinating them may help address risks that would otherwise remain overlooked.

Stigma and Confidentiality Can Influence Treatment Continuity

Tuberculosis remains associated with stigma in many communities.

People may worry about losing employment, experiencing social exclusion, or having their diagnosis disclosed without permission.

Some delay seeking medical assessment because they fear how others may respond. Others may find regular appointments difficult when attending a particular service could reveal their diagnosis.

These concerns can affect whether people seek care, report medication difficulties, disclose symptoms, or continue treatment.

Respectful communication is therefore important.

Patients should receive accurate information about transmission, treatment, and necessary precautions without being characterized as irresponsible or dangerous.

Family members and caregivers also need reliable information to avoid unnecessary fear and restrictions.

Confidentiality must be considered alongside lawful disease notification, contact investigation, and infection-control responsibilities.

Protecting personal information does not remove public health obligations, but those obligations should be carried out through authorized procedures that limit unnecessary disclosure.

Treatment support should avoid humiliation, inappropriate coercion, and unnecessary restrictions on personal autonomy.

The purpose of person-centered care is to make treatment understandable, accessible, and appropriate while maintaining safeguards necessary to protect others.

Respectful communication is not a substitute for effective tuberculosis treatment. It is one of the conditions that can help people remain engaged with it.

Continuity of Care Requires Reliable Healthcare Services

Tuberculosis care may involve specialist hospitals, outpatient clinics, community health services, and public health programs.

Patients may move between these services during diagnosis, treatment, and follow-up.

Someone may begin treatment at a specialist center and later need continuing care closer to home. Another person may relocate for employment while still receiving medication.

Without clear communication, important information about the regimen, drug susceptibility, adverse effects, and required monitoring may be lost.

Healthcare organizations should therefore maintain clear responsibilities throughout the treatment pathway.

Patients need to know where to obtain medication, who to contact when adverse effects develop, and what to do if they cannot attend an appointment.

Healthcare professionals need access to the clinical information necessary to maintain safe and effective treatment.

When financial or social barriers arise, available support services may help prevent avoidable interruptions.

Digital communication can sometimes improve continuity. Appointment reminders, agreed telephone contact, and selected digital monitoring tools may support communication between patients and healthcare teams.

However, these tools have limitations.

A reminder message cannot resolve a medication supply problem or lack of transportation. A digital monitoring event also does not independently establish that medication has been swallowed correctly or that treatment has been clinically effective.

Technology should support professional care rather than replace assessment, communication, and follow-up.

Evaluating Tuberculosis Care Requires More Than Counting Appointments

Healthcare organizations may record how many patients attend appointments, receive nutritional counseling, or participate in treatment-support activities.

These figures are useful for describing service delivery, but they do not independently demonstrate treatment success.

Clinically meaningful outcomes may include treatment completion, bacteriological response when applicable, treatment success, loss to follow-up, adverse events, recurrence, and mortality.

Drug-resistant tuberculosis may require additional monitoring and longer-term assessment.

Nutritional interventions should be evaluated according to the needs they are intended to address.

For someone experiencing undernutrition, relevant outcomes may include changes in weight, nutritional status, dietary intake, and physical recovery. However, weight gain is not proof of tuberculosis cure.

Providing food baskets establishes that support was delivered. It does not necessarily establish that tuberculosis incidence was reduced unless appropriate outcome evidence supports that conclusion.

Transmission prevention should also be evaluated through more than counting distributed masks or educational materials.

Healthcare organizations may examine whether suspected infectious tuberculosis is recognized promptly, whether appropriate prevention measures are implemented, and whether household contacts receive necessary assessment.

Patient experience also matters.

A treatment program may achieve good clinical outcomes while imposing substantial financial or social hardship on households.

Recognizing those burdens may help identify opportunities to improve accessibility and continuity.

Evaluation should connect clinical outcomes with the reliability of healthcare services and the experience of people receiving treatment.

Data collection should remain proportionate, clinically meaningful, and consistent with applicable confidentiality and personal data protection requirements.

Professional and Legal Considerations in Viet Nam

Lifestyle Medicine can contribute to tuberculosis care through evidence-based professional education, nutritional support, tobacco cessation, appropriate physical activity, psychological support, and attention to the circumstances affecting treatment.

However, diagnosing tuberculosis, interpreting microbiological investigations, selecting treatment regimens, determining infectiousness, managing drug-resistant disease, and prescribing preventive treatment are regulated clinical and public health activities.

In Viet Nam, the Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026, provides the principal framework for medical examination and treatment. [10]

The Law on Disease Prevention No. 114/2025/QH15, effective July 1, 2026, provides additional statutory context for communicable disease prevention and public health responsibilities. [11]

These legal provisions do not independently establish Lifestyle Medicine as a separately licensed clinical specialty or authorize an educational organization to provide regulated tuberculosis services.

Healthcare professionals and facilities must act within their qualifications, legally authorized scopes of practice, and applicable institutional requirements.

Decision No. 162/QĐ-BYT remains an important Vietnamese professional reference for tuberculosis diagnosis, treatment, and prevention.

The WHO recommendations published in 2025 and 2026 provide updated international evidence and guidance, but they do not automatically replace Vietnamese requirements or establish the nationwide availability of recommended medicines, nutritional products, or social support programs.

Confidentiality is also important because tuberculosis-related information can affect personal relationships, employment, and willingness to seek care.

The Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/NĐ-CP, both effective January 1, 2026, establish relevant requirements for the processing and protection of personal data. [12,13]

These requirements must be considered alongside lawful disease reporting, contact investigation, infection prevention, and other public health responsibilities.

Identifiable patient and household information should be accessed, collected, used, and disclosed only through appropriate legal and professional arrangements.

For the Vietnam Lifestyle Medicine Alliance (VLMA), the appropriate contribution is professional education, evidence appraisal, scientific knowledge exchange, and responsible collaboration.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. Its role is to support evidence-based Lifestyle Medicine through education, professional capability development, and responsible interpretation of scientific evidence.

Tuberculosis is a relevant topic for professional learning because it illustrates how nutrition, health behaviors, social conditions, and access to healthcare interact with established medical treatment.

Potential educational activities could address nutritional support in tuberculosis, interpretation of evidence on household food assistance, tobacco cessation, treatment continuity, and the relationship between recovery and infection prevention.

Such activities would benefit from collaboration with appropriately qualified tuberculosis specialists, public health professionals, clinical nutrition professionals, and other relevant practitioners.

These are potential directions for education and collaboration, not claims that VLMA provides tuberculosis diagnosis, treatment, contact investigation, infection-control services, or clinical follow-up.

The objective is to strengthen professional understanding while respecting the clinical and public health responsibilities required for effective tuberculosis care.

Supporting Recovery Without Losing Sight of the Infection

Tuberculosis illustrates an important boundary of evidence-based Lifestyle Medicine.

Healthy eating does not eliminate Mycobacterium tuberculosis. Exercise does not replace antimicrobial treatment. Stress management does not make an infectious person noninfectious, and healthy habits cannot compensate for an ineffective regimen.

However, these limitations do not make supportive interventions unimportant.

Undernutrition can worsen the burden of disease. Food insecurity can affect entire households. Tobacco use, harmful alcohol consumption, psychological distress, and limited access to services can complicate treatment and recovery.

Updated WHO recommendations recognize that comprehensive tuberculosis care may need to address these concerns alongside diagnosis, medication, and prevention.

For Viet Nam, this is particularly relevant as the country advances its tuberculosis strategy for 2026–2030, including earlier detection, stronger integration with primary healthcare, and improved treatment continuity.

The opportunity is not to develop an alternative Lifestyle Medicine treatment for tuberculosis. It is to connect nutritional assessment, recovery support, and attention to social needs with effective antimicrobial treatment and airborne transmission prevention.

Better care should help people complete treatment safely, reduce preventable transmission, recover physical function, and maintain dignity throughout the process.

Successful treatment depends not only on individual behavior, but also on access to medicines, reliable healthcare services, appropriate information, and practical support.

The value of Lifestyle Medicine in tuberculosis care lies in addressing health and recovery needs that extend beyond the infection, without losing sight of the antimicrobial treatment and public health measures essential to controlling it.

For healthcare professionals in Viet Nam, this provides a responsible foundation for integrating evidence-based lifestyle support into comprehensive tuberculosis care.

Selected References

1. World Health Organization. Global Tuberculosis Report 2025. Geneva: World Health Organization; November 12, 2025. ISBN: 978-92-4-011692-4.

2. World Health Organization Viet Nam. Speech of Dr. Angela Pratt at the 2025 Tuberculosis Annual Review and Launch of Viet Nam's National Tuberculosis Strategic Plan 2026–2030. Hanoi; May 7, 2026.

3. World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 4 — Treatment and Care. Second edition. Geneva: World Health Organization; September 25, 2026. ISBN: 978-92-4-012512-4.

4. Ministry of Health of Viet Nam. Decision No. 162/QĐ-BYT Issuing the Guidelines for Diagnosis, Treatment and Prevention of Tuberculosis. January 19, 2024.

5. World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 6 — Tuberculosis and Comorbidities. Second edition. Geneva: World Health Organization; October 7, 2025. ISBN: 978-92-4-011196-7.

6. Bhargava A, Bhargava M, Meher A, et al. Nutritional Supplementation to Prevent Tuberculosis Incidence in Household Contacts of Patients With Pulmonary Tuberculosis in India (RATIONS): A Field-Based, Open-Label, Cluster-Randomised Controlled Trial. The Lancet. 2023;402(10402):627–640. DOI: 10.1016/S0140-6736(23)01231-X.

7. World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 1 — Prevention: Infection Prevention and Control. Policy brief. Geneva: World Health Organization; September 2022. ISBN: 978-92-4-005588-9.

8. World Health Organization. WHO Operational Handbook on Tuberculosis: Module 1 — Prevention: Infection Prevention and Control. Geneva: World Health Organization; August 31, 2023. ISBN: 978-92-4-007815-4.

9. World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 1 — Prevention: Tuberculosis Preventive Treatment. Second edition. Geneva: World Health Organization; September 2024. ISBN: 978-92-4-009619-6.

10. Office of the National Assembly of Viet Nam. Consolidated Document No. 26/VBHN-VPQH: Law on Medical Examination and Treatment. February 26, 2026.

11. National Assembly of Viet Nam. Law on Disease Prevention No. 114/2025/QH15. December 10, 2025. Effective July 1, 2026.

12. National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. June 26, 2025. Effective January 1, 2026.

13. Government of Viet Nam. Decree No. 356/2025/NĐ-CP Detailing Certain Articles and Measures for Implementing the Law on Personal Data Protection. December 31, 2025. Effective January 1, 2026.

Editorial and Professional Scope Note

This article presents the professional perspective of the Vietnam Lifestyle Medicine Alliance on the supportive role and limitations of evidence-based Lifestyle Medicine in tuberculosis care, including nutrition, treatment continuity, recovery, tobacco cessation, and transmission prevention. It reflects scientific and regulatory information reviewed as of October 30, 2026.

The article is intended for professional information, education, and scientific knowledge exchange. It does not constitute an official clinical practice guideline, individualized medical advice, a diagnostic or treatment protocol, a nutritional prescription, an exercise prescription, an infection-control protocol, or an authoritative interpretation of Vietnamese law. The introductory scenario is hypothetical and does not describe an actual VLMA clinical activity.

Tuberculosis requires appropriate medical assessment and, when active disease is diagnosed, effective antimicrobial treatment. Lifestyle interventions must not replace, delay, or interrupt prescribed anti-tuberculosis medication or necessary clinical monitoring.

Determining tuberculosis infectiousness, selecting or modifying treatment regimens, managing adverse drug reactions, prescribing preventive treatment, and making decisions about isolation or return to work and school require appropriate clinical and public health assessment.

International WHO recommendations are provided for educational purposes. Their inclusion does not mean that they have automatically been adopted as Vietnamese clinical requirements or that all recommended medicines, nutritional interventions, and social support programs are available nationwide.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. It is not a licensed tuberculosis treatment facility, public health authority, medical licensing body, or healthcare accreditation organization. VLMA does not independently diagnose or treat tuberculosis, prescribe antimicrobial medication, determine infectiousness, conduct clinical contact investigations, or provide individualized patient follow-up.

Clinical and public health activities must remain under the responsibility of appropriately authorized professionals and organizations acting within applicable Vietnamese legal and institutional requirements.

Patient and household information must be handled in accordance with applicable confidentiality, personal data protection, and lawful public health reporting requirements.

The article does not endorse any commercial nutritional supplement, herbal product, medication brand, digital monitoring platform, or unproven treatment. References to scientific studies and professional guidance do not imply that VLMA has formally adopted, clinically implemented, evaluated, validated, or certified any tuberculosis care or Lifestyle Medicine program discussed in this article.